Ocular Therapeutix, Inc.
AXPAXLI
wet AMD
Resolved
87days ago
Phase 3 readout · Apr 11, 2026
What's at stake
Phase 3 trial results for AXPAXLI in wet AMD are due Apr 11, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“SOL-R Phase 3 non-inferiority trial in wet AMD on track for topline readout in 1Q 2027.”